Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Forkhead box protein L2 (FOXL2) is a forkhead/winged-helix DNA-binding transcription factor highly expressed in the ovary, pituitary, and eyelid muscle precursor tissues. FOXL2 is necessary for ovarian development, granulosa cell differentiation, and repression of testis-specific pathways in females. It modulates transcription of genes involved in steroidogenesis, apoptosis, and cell cycle control. Mutations in FOXL2 are associated with genetic syndromes such as BPES (with or without premature ovarian failure), sex reversal syndromes in animals, and a characteristic C134W alteration in adult granulosa cell tumors. FOXL2 cooperatively regulates TP53 and other cancer-relevant genes, affecting cell proliferation and apoptosis. It is conserved across mammals and vertebrates and is considered a master regulator of ovarian identity and granulosa cell fate.
Not directly applicable as FOXL2 is not the target of marketed drugs. In adult granulosa cell tumors, FOXL2 status (especially C134W mutation) is used diagnostically or for understanding tumor biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Forkhead box protein L2 (FOXL2).